In vitro profiling of pramiconazole and in vivo evaluation in Microsporum canis dermatitis and Candida albicans vaginitis laboratory models

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4927-4929

  De Wit, Kelly ^a   Paulussen, Caroline ^a   Matheeussen, An ^a   Van Rossem, Koen ^b   Cos, Paul ^a   Maes, Louis ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Stiefel Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ITRACONAZOLE; MICONAZOLE; PRAMICONAZOLE; TERBINAFINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CYTOTOXICITY; DERMATITIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; EXPERIMENTAL MODEL; FEMALE; GUINEA PIG; IC 50; IN VITRO STUDY; KLUYVEROMYCES MARXIANUS; MAXIMUM PLASMA CONCENTRATION; MICROSPORUM CANIS; MICROSPORUM CANIS INFECTION; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM; VAGINA MYCOSIS; VULVOVAGINITIS; ZYGOMYCETES;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; DERMATITIS; FEMALE; GUINEA PIGS; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; ITRACONAZOLE; MICROSPORUM; NAPHTHALENES; TRIAZOLES; VAGINITIS;

EID: 78049310322     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00730-10     Document Type: Article

References (24)

1. Ameen, M. 2010. Epidemiology of superficial fungal infections. Clin. Dermatol. 28:197-201.
2. Arikan, S., and J. H. Rex. 2007. Antifungal agents, p. 1949-1960. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
3. Ausma, J., G. Pennick, H. Bohets, V. van de Velde, M. Borgers, and A. Fothergill. 2007. Absence of an active metabolite for the triazole antifungal pramiconazole. Acta Derm. Venereol. 87:22-26.
4. Borgers, M., H. Degreef, and G. Cauwenberg. 2005. Fungal infections of the skin: infection process and antimycotic therapy. Curr. Drug Targets 6:849-862. (Pubitemid 41672447)
5. Boucher, H. W., A. H. Groll, C. Chiou, and T. J. Walsh. 2004. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 64:1997-2020.
6. Chayakulkeeree, M., M. A. Ghannoum, and J. R. Perfect. 2006. Zygomycosis: the re-emerging fungal infection. Eur. J. Clin. Microbiol. Infect. Dis. 25:215-229.
7. Cos, P., A. J. Vlietinck, D. V. Berghe, and L. Maes. 2006. Anti-infective potential of natural products: how to develop a stronger in vitro "proof-of-concept." J. Ethnopharmacol. 106:290-302.
8. Decroix, J., J. Ausma, G. Cauwenbergh, M. Borgers, and L. Wouters. 2008. The efficacy of oral treatment with pramiconazole in tinea pedis and tinea cruris/corporis: two exploratory phase IIa trials. Br. J. Dermatol. 158:854-856.
9. Donders, G., J. Ausma, L. Wouters, G. Cauwenbergh, M. Borgers, and D. Janssens. 2008. Efficacy of a single oral dose of 200 mg pramiconazole in vulvovaginal yeast infections: an exploratory phase IIa trial. Acta Derm. Venereol. 88:462-466.
10. Faergemann, J., J. Ausma, and M. Borgers. 2006. In vitro activity of R126638 and ketoconazole against Malassezia species. Acta Derm. Venereol. 86:1-4.
11. Faergemann, J., J. Ausma, L. Vandenplassche, and M. Borgers. 2007. The efficacy of oral treatment with pramiconazole in pityriasis versicolor: a phase IIa trial. Br. J. Dermatol. 156:1385-1387.
12. Geria, A. N., and N. S. Scheinfeld. 2008. Pramiconazole, a triazole compound for the treatment of fungal infections. IDrugs 11:661-670.
13. Gupta, A. K., and E. A. Cooper. 2008. Update in antifungal therapy of dermatophytosis. Mycopathologia 166:353-367.
14. Hainer, B. L. 2003. Dermatophyte infections. Pract. Ther. 67:101-108.
15. McCathie, R. 2006. Vaginal discharge: common causes and management. Curr. Obstet. Gynaecol. 16:211-217.
16. Meerpoel, L., L. J. J. Backx, L. J. E. Van der Veken, J. Heeres, D. Corens, A. De Groot, F. C. Odds, F. Van Gerven, F. A. A. Woestenborghs, A. Van Breda, M. Oris, P. Van Dorsselaer, G. H. M. Willemsens, K. J. P. Vermuyten, P. J. M. G. Marichal, H. F. Vanden Bossche, J. Ausma, and M. Borgers. 2005. Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. J. Med. Chem. 48:2184-2193.
17. Odds, F., J. Ausma, F. Van Gerven, F. Woestenborghs, L. Meerpoel, J. Heeres, H. Vanden Bossche, and M. Borger. 2004. In vitro and in vivo activities of the novel azole antifungal agent R126638. Antimicrob. Agents Chemother. 48:388-391.
18. Petranyi, G., J. G. Meingassner, and H. Mieth. 1987. Activity of terbinafine in experimental fungal infections of laboratory animals. Antimicrob. Agents Chemother. 31:1558-1561.
19. Piérard, G. E., J. Ausma, F. Henry, V. Vroome, L. Wouters, M. Borgers, G. Cauwenbergh, and C. Piérard-Franchimont. 2007. A pilot study on seborrheic dermatitis using pramiconazole as a potent oral anti-Malassezia agent. Dermatology 214:162-169. (Pubitemid 46377243)
20. Ryder, N. S., and B. Favre, 1997. Antifungal activity and mechanism of action of terbinafine. Rev. Contemp. Pharmacother. 8:275-287.
21. Sobel, J. D. 2007. Vulvovaginal candidosis. Lancet 369:1961-1971.
22. Sobue, S., K. Sekiguchi, and T. Nabeshima. 2004. Intracutaneous distributions of fluconazole, itraconazole, and griseofulvin in guinea pigs and binding to human stratum corneum. Antimicrob. Agents Chemother. 48:216-223.
23. Tiballi, R. N., X. He, L. T. Zarins, S. G. Revankar, and C. A. Kauffman. 1995. Use of a colorimetric system for yeast susceptibility testing. J. Clin. Microbiol. 33:915-917.
24. Treiber, A., W. Pitterman, and H. Schuppe. 2001. Efficacy testing of antimycotic prophylactics in an animal model. Int. J. Hyg. Environ. Health 204:1-5.